Production (Stage)
BetterLife Pharma Inc.
BETR
CNSX
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.88% | -18.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.56% | -14.97% | |||
| Operating Income | 25.56% | 14.97% | |||
| Income Before Tax | 73.01% | -214.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 73.01% | -214.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -114.03% | 173.42% | |||
| Net Income | 71.26% | -217.50% | |||
| EBIT | 25.56% | 14.97% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 72.50% | -217.65% | |||
| Normalized Basic EPS | 65.71% | -3,600.00% | |||
| EPS Diluted | 76.27% | -296.67% | |||
| Normalized Diluted EPS | 65.71% | -3,600.00% | |||
| Average Basic Shares Outstanding | 0.43% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.43% | -11.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||